DVC LLC

DynPort Vaccine Company LLC, a CSC company, manages product development programs for U.S. and international government agencies, and provides consulting services to biotechnology and pharmaceutical companies. More on what we do.

DynPort releases rBV A/B trial results

We released botulinum neurotoxin vaccine candidate Phase 2 clinical trial results on  January 24; rBV A/B was safe and well-tolerated in the trial.

Phacilitate Vaccine Forum
January 30-February 1, 2012
Visit us in booth 19 at Phacilitate in Washington, DC, or contact us to arrange a private meeting.

7th Annual CBRNe Defense Conference

January 30-February 1, 2012

Join government, military and industry leaders in Alexandria, VA to discuss detection technologies, reactive measures, and inter-agency cooperation.

DynPort named to Best Places to Work
DVC took top honors in the large business category for our family-friendly work environment and innovative benefits.

Biodefense and Pandemic Resources
Looking for more information on biological defense or pandemics? Check out our Biodefense and Pandemic Resources, including government and academic sites.

Why choose DVC?
You can't afford to pay for a learning curve. With DVC, you don't have to. Learn more about how we can help you.